Learn about KADCYLA® (ado-trastuzumab emtansine), a treatment for certain patients with early or metastatic HER2+ breast cancer. See Full Safety and Boxed Warnings for more information.

Discover how KADCYLA® (ado-trastuzumab emtansine) is thought to work for the treatment of HER2+ early breast cancer. See Full Safety and Boxed Warnings for more information.

Learn about possible side effects with KADCYLA® (ado-trastuzumab emtansine) for the treatment of HER2+ metastatic breast cancer. See Full Safety and Boxed Warnings for more information.

Read about KADCYLA® (ado-trastuzumab emtansine), a treatment for certain patients with HER2+ early breast cancer. See Full Safety and Boxed Warnings for more information.

Read about the treatment schedule for KADCYLA® (ado-trastuzumab emtansine), a treatment for HER2+ early breast cancer. See Full Safety and Boxed Warnings for more information.

Talk to a healthcare professional for more information about the benefits and risks of KADCYLA. Please see full Prescribing Information for Important Safety Information, including most serious …

KADCYLA is a prescription medicine used to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane.

Access helpful links and downloads related to KADCYLA® (ado-trastuzumab emtansine), a treatment option for HER2+ early breast cancer. See Full Safety and Boxed Warnings for more information.

Talk to a healthcare professional for more information about the benefits and risks of KADCYLA. Please see full Prescribing Information for Important Safety Information, including most serious …

Who is KADCYLA for? KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including a taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery.